Rationale and design of uLtrasOund applicability in the assessment of patients with fibRosing interstitial lung Disease (LORD): a research protocol of a prospective cohort study

Authors

Kristoffer Kittelmann Brockhattingen
Sanjeewa Patabendige (ORCID: https://orcid.org/0000-0002-6570-1997)
Christian Kildegaard
Christian B Laursen
Elisabeth Bendstrup
Stefan M W Harders
Michael T Durheim
Morten Bendixen

Institutions

Oslo University Hospital (NO)
Duke University (US)
University of Southern Denmark (DK)
Aarhus University (DK)
Odense University Hospital (DK)
Aarhus University Hospital (DK)
Clinical Research Institute (US)

Publication Details

Journal: BMJ Open
Published: 2026-02-01
DOI: https://doi.org/10.1136/bmjopen-2025-112171
Primary Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer
AstraZeneca
GlaxoSmithKline

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Rationale and design of uLtrasOund applicability in the assessment of patients with fibRosing interstitial lung Disease (LORD): a research protocol of a prospective cohort study

Kristoffer Kittelmann Brockhattingen, Sanjeewa Patabendige, Christian Kildegaard, Christian B Laursen et al.

Feb 1, 2026

BMJ Open

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

article

Rationale and design of uLtrasOund applicability in the assessment of patients with fibRosing interstitial lung Disease (LORD): a research protocol of a prospective cohort study

Kristoffer Kittelmann Brockhattingen, Sanjeewa Patabendige, Christian Kildegaard, Christian B Laursen, Elisabeth Bendstrup, Stefan M W Harders, Michael T Durheim, Morten Bendixen

February 1, 2026article en

Abstract

No abstract available for this paper.

BMJ OpenVol. 16(2)

Oslo University Hospital (NO), Duke University (US), University of Southern Denmark (DK), Aarhus University (DK), Odense University Hospital (DK), Aarhus University Hospital (DK), Clinical Research Institute (US)

Pfizer, AstraZeneca, GlaxoSmithKline

Partnerships for the goals

Openalex Percentile: Top 49%

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.